Vericel Corp Ord (VCEL)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	-3,182	-10,244	-13,161	-17,104	-16,700	-18,096	-16,450	-11,273	-7,471	214	8,763	4,280	2,864	145	-3	-11,526	-9,665	-13,924	-18,463	-3,322
Total stockholders’ equity	US$ in thousands	225,952	204,380	198,928	193,978	192,272	177,837	174,816	172,485	170,462	156,780	151,092	140,209	134,260	114,630	107,596	110,452	111,091	96,990	88,542	103,055
ROE		-1.41%	-5.01%	-6.62%	-8.82%	-8.69%	-10.18%	-9.41%	-6.54%	-4.38%	0.14%	5.80%	3.05%	2.13%	0.13%	-0.00%	-10.44%	-8.70%	-14.36%	-20.85%	-3.22%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-3,182K ÷ $225,952K
= -1.41%

Vericel Corp's return on equity (ROE) has fluctuated over the past eight quarters. The company's ROE has been negative, with the highest value recorded in Q4 2022 at -8.69% and the lowest in Q1 2023 at -8.82%. These figures indicate that Vericel Corp has been generating less profit with the equity provided by shareholders. The trend shows a gradual decrease in ROE from Q2 2022 to Q1 2023, with a slight improvement seen in Q4 2023 at -1.41%. The negative ROE values suggest that the company's profitability is relatively low compared to the equity invested, indicating potential inefficiencies in the utilization of shareholder funds. Further analysis of the company's financial performance and operational strategies may be necessary to address the declining ROE trend.